10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

MLP Antibody (Center) Blocking Peptide
Synthetic peptide
Catalog # BP2413b

Specification

MLP Antibody (Center) Blocking Peptide - Product Information

Primary Accession P49006

MLP Antibody (Center) Blocking Peptide - Additional Information

Gene ID 65108

Other Names
MARCKS-related protein, MARCKS-like protein 1, Macrophage myristoylated alanine-rich C kinase substrate, Mac-MARCKS, MacMARCKS, MARCKSL1, MLP, MRP

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP2413b was selected from the Center region of human MLP . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

MLP Antibody (Center) Blocking Peptide - Protein Information

Name MARCKSL1

Synonyms MLP, MRP

Function
Controls cell movement by regulating actin cytoskeleton homeostasis and filopodium and lamellipodium formation (PubMed:22751924). When unphosphorylated, induces cell migration (By similarity). When phosphorylated by MAPK8, induces actin bundles formation and stabilization, thereby reducing actin plasticity, hence restricting cell movement, including neuronal migration (By similarity). May be involved in coupling the protein kinase C and calmodulin signal transduction systems (By similarity).

Cellular Location

Cytoplasm, cytoskeleton {ECO:0000250|UniProtKB:P28667}. Cell membrane; Lipid- anchor. Note=Associates with the membrane via the insertion of the N-terminal N-myristoyl chain and the partial insertion of the effector domain. Association of the effector domain with membranes may be regulated by Ca(2+)/calmodulin. Colocalizes with F-actin at the leading edge of migrating cells (By similarity). In prostate cancers, shows strong expression at apical and/or basal regions of the cell and also has weak cytoplasmic expression (PubMed:22751924). {ECO:0000250|UniProtKB:P28667, ECO:0000269|PubMed:22751924}

MLP Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

MLP Antibody (Center) Blocking Peptide - Images

MLP Antibody (Center) Blocking Peptide - References

Hsia, T.C., et al., Lung 180(3):173-179 (2002).Stumpo, D.J., et al., Genomics 49(2):253-264 (1998).Umekage, T., et al., FEBS Lett. 286 (1-2), 147-151 (1991).